Compare State Street SPDR S&P Biotech ETF (XBI) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Zeta Global Holdings Corp — how do they compare? State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B), while Zeta Global Holdings Corp trades at $33.18 (market cap $8.29B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Zeta Global Holdings Corp is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Biotech ETF for 38 Days and Zeta Global Holdings Corp for 19 Days on average.
| XBI | ZETA | |
|---|---|---|
Market Cap | $10.11B | $8.29B |
Volume | 12,903,266 | 7,156,795 |
Sector | Broad Market / Factor | Technology |
52-Week High | $169.55 | $33.74 |
52-Week Low | $104.99 | $14.55 |
Typical Hold Time | 38 Days | 19 Days |
Enterprise Value | — | $8.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
ZETA trades at $33.63, down 0.33% on the day, showing resilience near its 52-week high territory. The stock maintains strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent expansion into the UK market and growing AI platform adoption support the positive sentiment, though negative net income margins and elevated valuation metrics warrant caution.
The outlook remains cautiously optimistic with 75% analyst buy ratings and a $32.40 consensus target. Key opportunities include accelerating revenue growth and AI-driven customer expansion, while risks involve negative profitability, high valuation multiples, and potential insider fiduciary concerns highlighted in recent shareholder notices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
